45 Pont Street
About RexgeneroRexgenero is a leading regenerative medicine company and developer of advanced cell-based therapeutics for the treatment of serious diseases that are poorly treated with existing therapies. We are conducting clinical trials with our stem cell therapies with the intention of obtaining marketing authorization in Europe the United States and other markets.
February 6, 2015
Chairman: Gaby Salem
Vice Chairman: Vicente Sáez González
CEO: Joe Dupere
COO: Edwin Wagena
VP, Manufacturing and Research & Development: Liesbeth de Jong
VP, Clinical and Regulatory Development: Karen Reitsma
Please click here for Rexgenero's technology.
Please click here for Rexgenero's pipeline.
10 articles with Rexgenero
8/22/2019Companies from across the globe provide updates on their business and pipelines.
Atelerix Consortium Awarded £267,000 Innovate UK Grant for Collaboration with the Cell and Gene Therapy Catapult and Rexgenero on Cell Therapy Stabilisation Technologies
Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischaemia, welcomes the news announced by Atelerix that it has been awarded a grant of £267,000 from Innovate UK.
First Czech Republic Diabetic Patient with Critical Limb Ischaemia Treated with Novel Regenerative Therapy by Associate Professor Václav Procházka at University Hospital Ostrava
Phase III SALAMANDER Trial of Rexgenero’s REX-001 Open and Recruiting
Rexgenero Successfully Expands Manufacturing of REX-001 through Partnership with German Red Cross Blood Donor Service
Enables new sites to participate in the European Phase III SALAMANDER trials
Rexgenero Presents Update on Phase III Clinical Trials with REX-001, a Cell-based Therapy for Critical Limb Ischaemia
At the Alliance for Regenerative Medicine’s Cell and Gene Therapy ‘Meeting on the Med’ in Barcelona
EMA Grants Rexgenero's Lead Product REX-001 Advanced Therapy Medicinal Product Certificate for Manufacturing Quality and Non-Clinical Data
The EMA certification paves the way for the MAA of its lead product REX-001, a novel cell therapy currently in a Phase III programme for the treatment of CLI.
The grant is a consortium between the Cell and Gene Therapy Catapult, TrakCel and Fisher Bioservices.
Consortium Including Trakcel Awarded GBP 1.4 Million From Innovate UK for Commercialisation of Rexgenero Cell Therapy
The project will focus on and design a cost effective commercial manufacturing strategy for Rexgenero's novel autologous cell therapy REX-001.
Rexgenero is pleased to announce today the appointment of Sam MacHour to its SAB.